REATA PHARMACEUTICALS INC
DelistedCIK 1358762fmd_02033HJ6HXEVTPGFJ26QBPDWB9Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2014 to Jun 30, 2023, 35 periods
Latest annual · FY2022
Millions- Total revenues
- 2
- Net income
- (312)
- Free cash flow
- (208)
Latest quarter · Q2 FY2023
Millions- Total revenues
- 23
- Net income
- 193
- Free cash flow
- (70)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2019 to FY2022
- -56.3%
- Revenue, 5 yearsFY2017 to FY2022
- -46.0%
- Net income, 5 yearsFY2017 to FY2022
- n/m
REATA PHARMACEUTICALS INC financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2022 | FY2021 | Change | Source |
|---|---|---|---|---|
| Revenue | $2.2 million | $11.5 million | -80.7% | 10-K 2023-02-24 · proof |
| Net income | -$311.9 million | -$297.4 million | 10-K 2023-02-24 · proof | |
| Cash from operating activities | -$204.3 million | -$235.7 million | 10-K 2023-02-24 · proof | |
| Free cash flow | -$207.5 million | -$237 million | 10-K 2023-02-24 · proof | |
| Total assets | $514.5 million | $735 million | -30% | 10-K 2023-02-24 · proof |
| Total liabilities | $580.2 million | $549 million | +5.7% | 10-K 2023-02-24 · proof |
| Cash and cash equivalents | $42.3 million | $590.3 million | -92.8% | 10-K 2023-02-24 · proof |
- What was REATA PHARMACEUTICALS INC's revenue in fiscal 2022?
- REATA PHARMACEUTICALS INC reported revenue of $2.2 million for fiscal 2022 (the year ended Dec 31, 2022), against $11.5 million the year before (-80.7%). Source: the 10-K filed with the SEC on Feb 24, 2023. SEC
- What was REATA PHARMACEUTICALS INC's net income in fiscal 2022?
- REATA PHARMACEUTICALS INC reported net income of -$311.9 million for fiscal 2022 (the year ended Dec 31, 2022), against -$297.4 million the year before. Source: the 10-K filed with the SEC on Feb 24, 2023. SEC
- What was REATA PHARMACEUTICALS INC's cash from operating activities in fiscal 2022?
- REATA PHARMACEUTICALS INC reported cash from operating activities of -$204.3 million for fiscal 2022 (the year ended Dec 31, 2022), against -$235.7 million the year before. Source: the 10-K filed with the SEC on Feb 24, 2023. SEC
- What was REATA PHARMACEUTICALS INC's free cash flow in fiscal 2022?
- REATA PHARMACEUTICALS INC reported free cash flow of -$207.5 million for fiscal 2022 (the year ended Dec 31, 2022), against -$237 million the year before. Source: the 10-K filed with the SEC on Feb 24, 2023. SEC
- What are REATA PHARMACEUTICALS INC's total assets?
- As of Dec 31, 2022, REATA PHARMACEUTICALS INC reported total assets of $514.5 million, against $735 million a year earlier (-30%). Source: the 10-K filed with the SEC on Feb 24, 2023. SEC
- What are REATA PHARMACEUTICALS INC's total liabilities?
- As of Dec 31, 2022, REATA PHARMACEUTICALS INC reported total liabilities of $580.2 million, against $549 million a year earlier (+5.7%). Source: the 10-K filed with the SEC on Feb 24, 2023. SEC
- What are REATA PHARMACEUTICALS INC's cash and cash equivalents?
- As of Dec 31, 2022, REATA PHARMACEUTICALS INC reported cash and cash equivalents of $42.3 million, against $590.3 million a year earlier (-92.8%). Source: the 10-K filed with the SEC on Feb 24, 2023. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1358762&period_type=annual&limit=5"Information only, not investment advice.